Loading stock data…
CERT
$5.13-1.18 (-18.70%)
Market ClosedLast close May 11
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Certara, Inc. in the Healthcare sector is trading at $5.13. The stock is currently near its 52-week low of $4.99, remaining 43.2% below its 200-day moving average. Technical signals show neutral RSI of 32 and bearish MACD signal, explaining why CERT maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 32) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.13
Potential Upside
5%
Whystock Fair Value$5.39
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Mi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.02B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
0.75%
Volume
Today's trading volume
8.07M
Recent News
Certara Inc (CERT) Q1 2026 Earnings Call Highlights: Navigating Modest Growth and Strategic ...
Despite a slight revenue increase, Certara Inc (CERT) focuses on AI advancements and strategic partnerships to drive future growth.
Certara (CERT) Q1 2026 Earnings Call Transcript
Since we last spoke, I have crossed over the 100-day mark at Certara, and I continue to be incredibly impressed by many things within the company. Certara products and services are integral to the drug development process and increasingly scalable through the use of AI technologies. Having exited the listening and learning phase, my attention has transitioned to helping Certara reach its full potential.
Certara (CERT) Shares Slide After Weak Full-Year Guidance Overshadows Revenue Beat
Certara, Inc. (NASDAQ:CERT) shares plunged more than 12% in premarket trading on Monday after the company issued weaker-than-expected full-year guidance despite reporting first-quarter revenue slightly ahead of forecasts.
Certara Q1 Earnings Call Highlights
Certara (NASDAQ:CERT) reported first-quarter 2026 revenue of $106.9 million, up 1% from the prior-year period, as stronger software performance offset softer services results and the company outlined a strategic reset under Chief Executive Officer Jon Resnick. Resnick, who said he has passed the 10
Certara, Inc. (CERT) Q1 Earnings Miss Estimates
Certara (CERT) delivered earnings and revenue surprises of -20.57% and +1.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?